国内外头颈部鳞癌指南循证评价(鼻咽癌除外)

Evidence-based Evaluation of Global Guidelines for Head and Neck Squamous Cell Carcinoma(Excepting Nasopharynx Cancer)

目的了解国内外头颈部鳞癌指南的发布状况、评价其质量,为我国制定头颈部鳞癌指南提供借鉴。方法计算机检索PubMed、Embase、NGC(U.S.National Guideline Clearing-house),CMA Infobase(the Canadian Medical Association Infobase),GIN(the Guidelines International Network),SIGN(the Scottish Intercollegiate Guidelines Network),the CMAdisc等中英文数据库和指南网站,按既定的纳入与排除标准,筛选文献,纳入符合标准的指南,用指南评价工具AGREE(Appraisal of Guideline for REsearch and Evaluation)Ⅱ对其进行质量评价。结果共检索出514篇相关文献,最终纳入49篇头颈部鳞癌指南,共覆盖15个国家、地区。现有指南主要由美国、加拿大、英国发布。49篇指南6个领域的得分分别为:71.63%、43.37%、45.63%、68.08%、32.41%、42.55%。结论国内外头颈部鳞癌指南的质量中等,国内可借鉴AGREE的评价体系结合国内实际制定高水平的临床指南。

Objective To review and evaluate the basic contents and development of the current global clinical guidelines for head and neck squamous cell carcinoma. Methods Seven databases, PubMed, Embase, NGC(U.S. National Guideline Clearing-house), CMA infobase(the Canadian Medical Association Infobase), GIN(the Guidelines International Network), SIGN(the Scottish Intercollegiate Guidelines Network) and the CMAdisc, were screened according to the predefi ned inclusion and exclusion criteria. The number of clinical guidelines was counted and the quality of guidelines was also assessed by AGREE( Appraisal of Guideline for REsearch and Evaluation) Ⅱ. Results A total of 514 articles were found to be clinical guideline-related and 49 articles were fi nally included. The guidelines were issued by 15 countries/regions, mainly by American, Canada and UK. Mean scores of six domains were 71.63%, 43.37%, 45.63%, 68.08%, 32.41% and 42.55%, respectively. Conclusion The quality of otorhinolaryngology guidelines in China is not high. China can be drawn lessons from the AGREE system and combined with domestic actual condition to making high level clinical guidelines.